Abstract
Recent evidence shows that hypoxia-inducible factor 2 alpha (HIF-2α) may have critical roles in the growth and progression of neuroblastoma (NB) under non-hypoxic conditions. However, the underlying mechanisms and clinical potentials of normoxic HIF-2α expression in NB still remain largely unknown. In this study, HIF-2α immunostaining was identified in 26/42 NB tissues, which was correlated with clinicopathological features. In subtotal 20 NB cases, microRNA-145 (miR-145) was downregulated and inversely correlated with HIF-2α expression. Bioinformatics analysis revealed a putative miR-145 binding site in the 3′-untranslated region (3′-UTR) of HIF-2α messenger RNA (mRNA). Overexpression or knockdown of miR-145 responsively altered both the mRNA and protein levels of HIF-2α and its downstream genes, cyclin D1, matrix metalloproteinase 14 and vascular endothelial growth factor, in normoxically cultured NB cell lines SH-SY5Y and SK-N-SH. In a luciferase reporter system, miR-145 downregulated the luciferase activity of HIF-2α 3′-UTR, and these effects were abolished by a mutation in the putative miR-145-binding site. Overexpression of miR-145 suppressed the growth, invasion, metastasis and angiogenesis of SH-SY5Y and SK-N-SH cells in vitro and in vivo, while restoration of HIF-2α expression rescued the tumor cells from miR-145-mediated defects in these biological features. Furthermore, anti-miR-145 inhibitor rescued the HIF-2α knockdown-mediated repression on the growth, migration, invasion and angiogenesis of NB cells. These data indicate that miR-145 suppresses HIF-2α expression via the binding site in the 3′-UTR under normoxic conditions, thus inhibiting the aggressiveness and angiogenesis of NB.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Ara T, DeClerck Y . Mechanisms of invasion and metastasis in human neuroblastoma. Cancer Metastasis Rev 2006; 25: 645–657.
Holmquist-Mengelbier L, Fredlund E, Löfstedt T, Noguera R, Navarro S, Nilsson H et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 2006; 10: 413–423.
Stallings RL . MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics. Curr Pharm Des 2009; 15: 456–462.
Wei JS, Song YK, Durinck S, Chen QR, Cheuk ATC, Tsang P et al. The MYCN oncogene is a direct target of miR-34a. Oncogene 2008; 27: 5204–5213.
Foley NH, Bray IM, Tivnan A, Bryan K, Murphy DM, Buckley PG et al. MicroRNA-184 inhibits neuroblastoma cell survival through targeting the serine/threonine kinase AKT2. Mol Cancer 2010; 9: 83.
Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M et al. Antagomir-17-5p abolishes the growth of therapy-resistant neuroblastoma through p21 and BIM. PLoS One 2008; 3: e2236.
Landgraf P, Rusu M, Sheridan R, Sewer A, Iovino N, Aravin A et al. A mammalian microRNA expression atlas based on small RNA library sequencing. Cell 2007; 129: 1401–1414.
Michael MZ, O’ Connor SM, van Holst Pellekaan NG, Young GP, James RJ . Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 2003; 1: 882–891.
Chiyomaru T, Tatarano S, Kawakami K, Enokida H, Yoshino H, Nohata N et al. SWAP70, actin-binding protein, function as an oncogene targeting tumor-suppressive miR-145 in prostate cancer. Prostate (e-pub ahead of print 25 February 2011; doi:10.1002/pros.21372).
Wang S, Bian C, Yang Z, Bo Y, Li J, Zeng L et al. miR-145 inhibits breast cancer cell growth through RTKN. Int J Oncol 2009; 34: 1461–1466.
Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma. Int J Cancer 2010; 127: 2804–2814.
Fischer L, Hummel M, Korfel A, Lenze D, Joehrens K, Thiel E . Differential micro-RNA expression in primary CNS and nodal diffuse large B-cell lymphomas. Neuro Oncol 2011; 13: 1090–1098.
Koo S, Martin G, Schulz K, Ronck M, Toussaint L . Serial selection for invasiveness increases expression of miR-143/miR-145 in glioblastoma cell lines. BMC Cancer 2012; 12: 143.
Zheng LD, Tong QS, Tang ST, Du ZY, Liu Y, Jiang GS et al. Expression and clinical significance of heparanase in neuroblastoma. World J Pediatr 2009; 5: 206–210.
Baba M, Hirai S, Yamada-Okabe H, Kenji H, Tabuchi H, Kobayashi K et al. Loss of von Hippel-Lindau protein causes cell density dependent deregulation of CyclinD1 expression through Hypoxia-inducible factor. Oncogene 2003; 22: 2728–2738.
Petrella BL, Lohi J, Brinckerhoff CE . Identification of membrane type-1 matrix metalloproteinase as a target of hypoxia-inducible factor-2 alpha in von Hippel-Lindau renal cell carcinoma. Oncogene 2004; 24: 1043–1052.
Raval RR, Lau KW, Tran MGB, Sowter HM, Mandriota SJ, Li JL et al. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau- associated renal cell carcinoma. Mol Cell Biol 2005; 25: 5675–5686.
Covello KL, Simon MC, Keith B . Targeted replacement of hypoxia-inducible factor-1alpha by a hypoxia-inducible factor-2alpha knock-in allele promotes tumor growth. Cancer Res 2005; 65: 2277–2286.
Shi B, Sepp-Lorenzino L, Prisco M, Linsley P, deAngelis T, Baserga R . MicroRNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells. J Biol Chem 2007; 282: 32582–32590.
Zhang J, Guo H, Zhang H, Wang H, Qian G, Fan X et al. Putative tumor suppressor miR-145 inhibits colon cancer cell growth by targeting oncogene friend leukemia virus integration 1 gene. Cancer 2011; 117: 86–95.
Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci USA 2009; 106: 3207–3212.
Zou C, Xu Q, Mao F, Li D, Bian C, Liu LZ et al. MiR-145 inhibits tumor angiogenesis and growth by N-RAS and VEGF. Cell Cycle 2012; 11: 2137–2145.
Götte M, Mohr C, Koo CY, Stock C, Vaske AK, Viola M et al. miR-145-dependent targeting of junctional adhesion molecule A and modulation of fascin expression are associated with reduced breast cancer cell motility and invasiveness. Oncogene 2010; 29: 6569–6580.
Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C et al. The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 2013; 32: 491–501.
Speranza MC, Frattini V, Pisati F, Kapetis D, Porrati P, Eoli M et al. NEDD9, a novel target of miR-145, increases the invasiveness of glioblastoma. Oncotarget 2012; 3: 723–734.
Xu Q, Liu LZ, Qian X, Chen Q, Jiang Y, Li D et al. MiR-145 directly targets p70S6K1 in cancer cells to inhibit tumor growth and angiogenesis. Nucleic Acids Res 2012; 40: 761–774.
Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjölund J, Gisselsson D et al. HIF-2 alpha maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 2009; 106: 16805–16810.
Cha ST, Chen PS, Johansson G, Chu CY, Wang MY, Jeng YM et al. MicroRNA-519c suppresses hypoxia-inducible factor-1alpha expression and tumor angiogenesis. Cancer Res 2010; 70: 2675–2685.
Lei Z, Li B, Yang Z, Fang H, Zhang GM, Feng ZH et al. Regulation of HIF-1alpha and VEGF by miR-20b tunes tumor cells to adapt to the alteration of oxygen concentration. PLoS One 2009; 4: e7629.
Acker T, ez-Juan A, Aragones J, Tjwa M, Brusselmans K, Moons L et al. Genetic evidence for a tumor suppressor role of HIF-2 alpha. Cancer Cell 2005; 8: 131–141.
Poincloux R, Lizárraga F, Chavrier P . Matrix invasion by tumour cells: a focus on MT1-MMP trafficking to invadopodia. J Cell Sci 2009; 122: 3015–3024.
Aplin AC, Zhu WH, Fogel E, Nicosia RF . Vascular regression and survival are differentially regulated by MT1-MMP and TIMPs in the aortic ring model of angiogenesis. Am J Physiol Cell Physiol 2009; 297: C471–C480.
Liu H, Kohane IS . Tissue and process specific microRNA-mRNA co-expression in mammalian development and malignancy. PLoS One 2009; 4: e5436.
Arndt GM, Dossey L, Cullen LM, Lai A, Druker R, Eisbacher M et al. Characterization of global microRNA expression reveals oncogenic potential of miR-145 in metastatic colorectal cancer. BMC Cancer 2009; 9: 374.
Borel C, Antonarakis SE . Functional genetic variation of human miRNAs and phenotypic consequences. Mamm Genome 2008; 19: 503–509.
Nicoloso MS, Sun H, Spizzo R, Kim H, Wickramasinghe P, Shimizu M et al. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility. Cancer Res 2010; 70: 2789–2798.
Zheng L, Jiang G, Mei H, Pu J, Dong J, Hou X et al. Small RNA interference-mediated gene silencing of heparanase abolishes the invasion, metastasis and angiogenesis of gastric cancer cells. BMC Cancer 2010; 10: 33.
Dweep H, Sticht C, Pandey P, Gretz N . miRWalk—database: prediction of possible miRNA binding sites by ‘walking’ the genes of three genomes. J Biomed Inform 2011; 44: 839–847.
Chae KS, Kang MJ, Lee JH, Ryu BK, Lee MG, Her NG et al. Opposite functions of HIF-α isoforms in VEGF induction by TGF-β1 under non-hypoxic conditions. Oncogene 2011; 30: 1213–1228.
Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. miR-9, a MYC/MYCN- activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 2010; 12: 247–256.
Acknowledgements
This work was supported by the National Natural Science Foundation of China (Nos. 30600278, 30772359, 81071997, 81072073, 81272779), Program for New Century Excellent Talents in University (NCET-06-0641), Scientific Research Foundation for the Returned Overseas Chinese Scholars (2008–889) and Fundamental Research Funds for the Central Universities (2012QN224).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies the paper on the Oncogene website
Supplementary information
Rights and permissions
About this article
Cite this article
Zhang, H., Pu, J., Qi, T. et al. MicroRNA-145 inhibits the growth, invasion, metastasis and angiogenesis of neuroblastoma cells through targeting hypoxia-inducible factor 2 alpha. Oncogene 33, 387–397 (2014). https://doi.org/10.1038/onc.2012.574
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2012.574